A device for the genetic detection of pathogenic bacteria has emerged from microfluidics research coupled with NMR spectroscopy
Portable TB Detector
Uncategorized
Comments Off on Portable TB Detector
Jun 142013
Does This Pipeline Promise Tomorrow’s Blockbuster Sales?
Uncategorized
Comments Off on Does This Pipeline Promise Tomorrow’s Blockbuster Sales?
Jun 142013
Does This Pipeline Promise Tomorrow’s Blockbuster Sales?
DailyFinance
The company currently has six drugs and indications under review for regulatory approval, with 15 more therapies undergoing phase 3 trials as of May 6. Those 21 drugs in total match up well with some of the top pipelines in the business. As a …http://www.dailyfinance.com/2013/06/12/does-this-pipeline-promise-tomorrows-blockbuster-s/
Tumor Immunotherapy Efficacy Increased In Both Breast And Prostate Cancer Preclinical Models With Addition Of Galectin Inhibitor
Uncategorized
Comments Off on Tumor Immunotherapy Efficacy Increased In Both Breast And Prostate Cancer Preclinical Models With Addition Of Galectin Inhibitor
Jun 132013
Tumor Immunotherapy Efficacy Increased In Both Breast And Prostate Cancer …
Daily Markets
NORCROSS, Ga., June 12, 2013 /PRNewswire-USNewswire/ — Galectin Therapeutics (GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that preclinical studies have shown that … The …
Emory University launches drug commercialization venture
Uncategorized
Comments Off on Emory University launches drug commercialization venture
Jun 132013
- Urvaksh Karkaria
- Staff Writer- Atlanta Business Chronicle
Emory University launches drug commercialization venture
DRIVE will provide the financial, business, project management and regulatory expertise to effectively move drugs through pre-clinical testing – a stage of drug development often termed the “Valley of Death” — and into proof-of-concept clinical trials.
read all at
Celgene arthritis drug maintains efficacy at 52 weeks-study
Uncategorized
Comments Off on Celgene arthritis drug maintains efficacy at 52 weeks-study
Jun 132013
apremilast
Celgene arthritis drug maintains efficacy at 52 weeks-study
Reuters
The U.S. biotechnology company had previously released positive data from the 500-patient Phase III trial called Palace-1 that compared its drug, apremilast, to a placebo through 16 weeks of treatment. The data being presented at the European League …
http://in.reuters.com/article/2013/06/11/celgene-arthritis-idINL2N0EN21P20130611
Apremilast is an orally available small molecule inhibitor of PDE4 being developed by Celgene for ankylosing spondylitis, psoriasis, and psoriatic arthritis.The drug is currently in phase III trials for the three indications. Apremilast, an anti-inflammatory drug, specifically inhibits phosphodiesterase 4. In general the drug works on an intra-cellular basis to moderate proinflammatory and anti-inflammatory mediator production.
Medical Use [Apremilast is being tested for its efficacy in treating “psoriasis, psoriatic arthritis and other chronic inflammatory diseases such as ankylosing spondylitis, Behcet’s disease, and rheutmatoid arthritis.”
Apremilast is being tested for its efficacy in treating “psoriasis, psoriatic arthritis and other chronic inflammatory diseases such as ankylosing spondylitis, Behcet’s disease, and rheutmatoid arthritis.”
Generic Licensing News, Featured product, Bosentan
Uncategorized
Comments Off on Generic Licensing News, Featured product, Bosentan
Jun 122013
http://www.leadformix.com/ef1/preview_campaign.php?lf1=900485181e199412625317a3906967
Click here to contact Zack Systems SpA about this product.
BOSENTAN
Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH).
Bosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin’s deleterious effects.
bosentan
Bosentan is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer.
Bosentan is indicated mainly for the treatment of pulmonary hypertension. In 2007, bosentan was approved in the European Union also for reducing the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.Bosentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes pulmonary vasoconstriction. By blocking this interaction, bosentan decreases pulmonary vascular resistance. Bosentan has a slightly higher affinity for ET-A than ET-B.
In the United States, bosentan is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO Class II-IV symptoms, to improve exercise capacity and decrease the rate of clinical worsening.[1]
Warnings
Due to potential hepatotoxicity, the FDA requires monthly monitoring of liver function tests while taking Bosentan.
Bosentan use requires hematocrit monitoring due to potential onset of anemia. [2]
Hormone-based contraception is not possible in women taking Bosentan, due to a pharmacokinetic interaction. [3]
Bosentan is absolutely contraindicated in pregnancy because of its teratogenicity. Category X.
- http://www.tracleer.com/pdf/09%20276%2001%2000%200809_Tra%20PI_4%20Pg_081409pdf.pdf
- http://www.ionchannels.org/showabstract.php?pmid=15875338
- http://www.ionchannels.org/showabstract.php?pmid=15875338
Clovis Oncology Shares Double on Trial Data for Cancer Drug,CO-1686
phase 1, Uncategorized
Comments Off on Clovis Oncology Shares Double on Trial Data for Cancer Drug,CO-1686
Jun 042013
Colorado-based Clovis said in a statement today. The drug, CO-1686, is in the first of three phases of testing typically required before U.S. regulatory approval.
http://www.businessweek.com/news/2013-06-03/clovis-oncology-shares-almost-double-on-ovarian-drug-trial-data
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
Selumetinib is the first drug ever to show significant benefit for patients with advanced uveal melanoma
Uncategorized
Comments Off on Selumetinib is the first drug ever to show significant benefit for patients with advanced uveal melanoma
Jun 042013
Two Array Invented MEK Inhibitors Showcased At ASCO
Sacramento Bee
AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.
http://www.sacbee.com/2013/06/03/5466446/two-array-invented-mek-inhibitors.html
Two Array BioPharma-invented MEK inhibitors, selumetinib and MEK162, were showcased at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
Experimental Drug Shows Benefits Against Melanoma in Early Study, Lambrolizumab activates body’s immune system to kill cancerous cells, researchers say
Uncategorized
Comments Off on Experimental Drug Shows Benefits Against Melanoma in Early Study, Lambrolizumab activates body’s immune system to kill cancerous cells, researchers say
Jun 032013
Experimental Drug Shows Benefits Against Melanoma in Early Study
U.S. News & World Report
SUNDAY, June 2 (HealthDay News) — A new drug called lambrolizumab appears to improve outcomes in patients with advanced melanoma, according to the results of a phase 1 trial. Lambrolizumab is an antibody that works by revealing the cancer to the immune system so it can mount a response and kill the cancer cells with few serious side effects, the researchers said.
read all at
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
Immune-Based Drug Shows Promise Against Advanced Melanoma
Uncategorized
Comments Off on Immune-Based Drug Shows Promise Against Advanced Melanoma
Jun 022013